HIV drug under review as firm withdraws FDA application.
Sidley
Pat
P
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D017277:Drug Approval; D015658:HIV Infections / Q000517:prevention & control*; D006801:Humans; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D019829:Nevirapine / Q000627:therapeutic use*; D013019:South Africa; D014481:United States; D014486:United States Food and Drug Administration
D019380:Anti-HIV Agents; D019829:Nevirapine